Drug intelligence / Profile preview

APN-sEV

Development stage: Preclinical
Lead developer: Ciloa
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes

Overview

APN-sEV (also known as CILO-101) is a bioengineered small extracellular vesicle (sEV) biotherapeutic developed by Ciloa. The candidate utilizes Ciloa's proprietary platform to incorporate recombinant multimerized native adiponectin onto the surface of sEVs, enabling the activation of the adiponectin receptor pathway. By targeting AdipoR1, AdipoR2, and T-cadherin, APN-sEV is designed to address a range of metabolic and inflammatory conditions, including obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular diseases, and retinopathies. The program is currently in the preclinical stage of development.

Other names: CILO-101CILO101CILO 101

Targets

ADIPOR2 (Adiponectin receptor 2)NFKB1 (NF-κB1)ADIPOR1 (Adiponectin receptor 1)

Beyond the preview

Go deeper on APN-sEV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APN-sEV.

Explore the full profile